Astellas Pharma Inc.

Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration [Press Release]
Business Wire | 1 day 1 hour 53 minutes ago
Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies’ antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

NeurogesX to Present at Piper Jaffray Health Care Conference [Press Release]
PRNewswire | 1 minute ago
...postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc. The Company's second most advanced product candidate, NGX-1998...

Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome [Press Release]
Business Wire | 5 days 4 hours 23 minutes ago
Astellas Pharma Inc. and XenoPort, Inc. (NASDAQ:XNPT) today announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin enacarbil), also known as XP13512, as a potential treatment for restless legs syndrome (RLS). The data supporting safety and efficacy in the NDA filing comes from the successful Phase 2 study in RLS patients and long-term safety study conducted by Astellas in Japan and the RLS clinical ...

NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director [Press Release]
PRNewswire | 1 minute ago
...postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc. The Company's second most advanced product candidate, NGX-1998...

Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide [Press Release]
PRNewswire | 14 days 3 hours 23 minutes ago
...Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they...collaborating with them." Astellas Pharma Inc., located in Tokyo, Japan...transplant. For more information on Astellas Pharma Inc., please visit www.astellas...

Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States [Press Release]
MarketWire | 18 days 12 hours 48 minutes ago
SOUTH SAN FRANCISCO, CA and DEERFIELD, IL -- (Marketwire) -- 11/05/09 -- Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV(TM) (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicill...

Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe [Press Release]
MarketWire | 26 days 14 hours 23 minutes ago
TOKYO and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/28/09 -- Astellas Pharma Inc. (Astellas) and Theravance, Inc. (NASDAQ: THRX) announced today that Astellas Pharma Europe B.V. submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for telavancin, a bactericidal, once-daily injectable lipoglycopeptide antibiotic, for the treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia, and complicated skin and soft tissue infection...

Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer [Press Release]
PRNewswire | 27 days 23 hours 23 minutes ago
...FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that...the most frequently reported adverse event. Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical...

Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back [Press Release]
PRNewswire | 63 days 2 hours 49 minutes ago
...DEERFIELD, Ill., Sept. 22 /PRNewswire/ -- Astellas Pharma US, Inc. has announced the winners of the first annual...Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to "Changing...

Photos: Astellas Celebrates the Miracle of Transplantation by Sending Five Recipients to the 2010 Rose Parade(R) [Press Release]
PRNewswire | 70 days 2 hours 49 minutes ago
...DEERFIELD, Ill., Sept. 15 /PRNewswire/ -- Astellas Pharma US, Inc. today announced the winners of the Astellas...Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to "Changing...

Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators [Press Release]
PRNewswire | 64 days 1 hour 21 minutes ago
...DEERFIELD, Ill., Sept. 21 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), in partnership with the...Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving...

Donate Life Illinois, Astellas and the Chicago Bears Partner to Tackle the Shortage in Honor of Bears Legend, Walter Payton [Press Release]
PRNewswire | 28 days 21 hours 53 minutes ago
...of Payton, Donate Life Illinois (DLI) and Astellas Pharma US, Inc., (Astellas) in partnership with the Chicago...Illinois, is a US affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving...

Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial [Press Release]
PRNewswire | 26 days 13 hours 55 minutes ago
NASDAQ: CRME TSX: COM